Ignite Creation Date:
2024-05-06 @ 7:55 PM
Last Modification Date:
2024-10-26 @ 3:17 PM
Study NCT ID:
NCT06188676
Status:
RECRUITING
Last Update Posted:
2024-01-03
First Post:
2023-03-06
Brief Title:
Multicenter Study of Safety and Efficacy Nivolumab at the Fixed Dose 40 mg Nivo40 in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed PMBL
Sponsor:
National Research Center for Hematology Russia
Organization:
National Research Center for Hematology Russia
Organization Data
Organization:
National Research Center for Hematology Russia
Class:
NETWORK
Study ID:
PMBL-2022
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
National Research Center for Hematology Russia
Lead Sponsor Class:
NETWORK
Responsible Party:
Elena NParovichnikova
Responsible Party Title:
Vice-director Nathional Medical Research Center for Hematology Moscow Russia
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
National Research Center for Hematology Russia
Old Name:
None
Old Organization:
None